NCT04648202View on ClinicalTrials.gov

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions
Advanced CancerMetastatic Cancer
Interventions
DRUG

FS120

Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.

Trial Locations (9)

28040

Hospital Universitario Fundacion Jimenez Diaz, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

46010

Hospital Clinico Universitario de Valencia, Valencia

77030

MD Anderson Cancer Center, Houston

78229

South Texas Accelerated Research Therapeutics (START), San Antonio

84112

Huntsman Cancer Institute, University of Utah, Salt Lake City

06511

Yale University, New Haven

08023

NEXT Oncology, Hospital Quironsalud Barcelona, Barcelona

08035

Hospital Universitario Vall d'Hebron, Barcelona

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

invoX Pharma Limited

INDUSTRY